We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Gossamer Bio Inc
5 own
10 watching
Current Price
$1.3
$-0.01
(-0.76%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
124.08M
52-Week High
15.195
52-Week Low
0.9103
Average Volume
3.93M
Dividend Yield
--
P/E Ratio
--
Market Capitalization124.08M52-Week High15.19552-Week Low0.9103Average Volume3.93MDividend Yield--P/E Ratio--What does the Gossamer Bio Inc do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It has license agreement with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More
How much money does Gossamer Bio Inc make?
News & Events about Gossamer Bio Inc.
Ticker Report
1month ago
Shares of Gossamer Bio, Inc. (NASDAQ:GOSS Get Rating) have received a consensus rating of Hold from the fourteen research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six...
Zolmax
2 months ago
Gossamer Bio, Inc. (NASDAQ:GOSS Get Rating) CEO Faheem Hasnain bought 440,500 shares of the stock in a transaction that occurred on Wednesday, March 22nd. The shares were purchased at an average cost of $1.14 per share, with a total value of $502,170.00. Following the purchase, the chief executive ...
Ticker Report
2 months ago
Gossamer Bio, Inc. (NASDAQ:GOSS Get Rating) HC Wainwright issued their FY2027 earnings estimates for Gossamer Bio in a research note issued to investors on Tuesday, March 21st. HC Wainwright analyst P. Trucchio anticipates that the company will earn ($0.59) per share for the year. HC...
Zolmax
2 months ago
Gossamer Bio (NASDAQ:GOSS Get Rating) had its price objective cut by investment analysts at Barclays from $2.00 to $1.50 in a note issued to investors on Tuesday, The Fly reports. The firm presently has an equal weight rating on the stock. Barclayss target price points to a potential upside of 35.14...
Business Wire
2 months ago
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended...
Frequently Asked Questions
Frequently Asked Questions
What is Gossamer Bio Inc share price today?
Can Indians buy Gossamer Bio Inc shares?
How can I buy Gossamer Bio Inc shares from India?
Can Fractional shares of Gossamer Bio Inc be purchased?
What are the documents required to start investing in Gossamer Bio Inc stocks?
What is today’s traded volume of Gossamer Bio Inc?
What is today’s market capitalisation of Gossamer Bio Inc?
What is the 52-Week High and Low Range of Gossamer Bio Inc?
What percentage is Gossamer Bio Inc down from its 52-Week High?
What percentage is Gossamer Bio Inc up from its 52-Week Low?
Current Price
$1.3
$-0.01
(-0.76%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.